Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis

Neurology

Volumn 63, Issue 12, 2004, Pages 2396-2398

  Badrising, U A ^a   Schreuder, G M Th ^a   Giphart, M J ^a   Geleijns, K ^a   Verschuuren, J J G M ^a   Wintzen, A R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B8 ANTIGEN; HLA DR3 ANTIGEN;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CELIAC DISEASE; CONTROLLED STUDY; EATON LAMBERT SYNDROME; FEMALE; GENE LINKAGE DISEQUILIBRIUM; HAPLOTYPE; HASHIMOTO DISEASE; HUMAN; IMMUNOPATHOGENESIS; INCLUSION BODY MYOSITIS; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SJOEGREN SYNDROME; ULCERATIVE COLITIS; VITILIGO;

EID: 11144270207     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000148588.15052.4C     Document Type: Article

References (10)

1. Badrising UA, Maat-Schieman ML, Ferrari MD, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002;51:369-372.
2. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000;55:1385-1387.
3. Schipper RF, Schreuder GM, D'Amaro J, Oudshoorn M. HLA gene and haplotype frequencies in Dutch blood donors. Tissue Antigens 1996;48: 562-574.
4. Garlepp MJ, Laing B, Zilko PJ, Ollier W, Mastaglia FL. HLA associations with inclusion body myositis. Clin Exp Immunol 1994;98:40-45.
5. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360-374.
6. Koffman BM, Sivakumar K, Simonis T, Stroncek D, Dalakas MC. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol 1998;84:39-142.
7. Wirtz PW, Roep BO, Schreuder GM, et al. HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor. Hum Immunol 2001;62:809-813.
8. Beyenburg S, Zierz S, Jerusalem F. Inclusion body myositis: clinical and histopathological features of 36 patients. Clin Invest 1993;71:351-361.
9. Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 1998;21:115-117.
10. Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis. Observations in 40 patients. Brain 1989;112:727-747.